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Caveolin-1 is required for TGF-b-induced
transactivation of the EGF receptor pathway in
hepatocytes through the activation of the
metalloprotease TACE/ADAM17
J Moreno-Ca`ceres1, L Caja1, J Mainez2, R Mayoral3,4, P Martı´n-Sanz4,5, R Moreno-Vicente6, MA´ del Pozo6, S Dooley7, G Egea2
and I Fabregat*,1,8
Transforming growth factor-beta (TGF-b) plays a dual role in hepatocytes, inducing both pro- and anti-apoptotic responses,
whose balance decides cell fate. Survival signals are mediated by the epidermal growth factor receptor (EGFR) pathway, which is
activated by TGF-b in these cells. Caveolin-1 (Cav1) is a structural protein of caveolae linked to TGF-b receptors trafficking and
signaling. Previous results have indicated that in hepatocytes, Cav1 is required for TGF-b-induced anti-apoptotic signals, but the
molecular mechanism is not fully understood yet. In this work, we show that immortalized Cav1 / hepatocytes were more
sensitive to the pro-apoptotic effects induced by TGF-b, showing a higher activation of caspase-3, higher decrease in cell
viability and prolonged increase through time of intracellular reactive oxygen species (ROS). These results were coincident with
attenuation of TGF-b-induced survival signals in Cav1 / hepatocytes, such as AKT and ERK1/2 phosphorylation and NFj-B
activation. Transactivation of the EGFR pathway by TGF-b was impaired in Cav1 / hepatocytes, which correlated with lack of
activation of TACE/ADAM17, the metalloprotease responsible for the shedding of EGFR ligands. Reconstitution of Cav1 in
Cav1 / hepatocytes rescued wild-type phenotype features, both in terms of EGFR transactivation and TACE/ADAM17
activation. TACE/ADAM17 was localized in detergent-resistant membrane (DRM) fractions in Cav1þ /þ cells, which was not the
case in Cav1 / cells. Disorganization of lipid rafts after treatment with cholesterol-binding agents caused loss of
TACE/ADAM17 activation after TGF-b treatment. In conclusion, in hepatocytes, Cav1 is required for TGF-b-mediated activation of
the metalloprotease TACE/ADAM17 that is responsible for shedding of EGFR ligands and activation of the EGFR pathway, which
counteracts the TGF-b pro-apoptotic effects. Therefore, Cav1 contributes to the pro-tumorigenic effects of TGF-b in liver cancer
cells.
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The transforming growth factor-beta (TGF-b) belongs to a
family of polypeptide factors, whose cytostatic and apoptotic
functions help restrain the growth of mammalian cells.
However, paradoxically, TGF-b also modulates processes
such as cell invasion, immune regulation and microenviron-
ment modification, which cancer cells may exploit to
their advantage.1 Indeed, a better knowledge about the
mechanistic basis and clinical relevance of TGF-b is required
for a better understanding of the complexity and therapeutic
potential of this pathway. In hepatocytes, TGF-b induces both
pro- and anti-apoptotic signals, whose balance decides cell
fate.2 Those hepatocytes that survive to TGF-b-mediated
apoptosis induce an epithelial–mesenchymal transition (EMT)
process, which confers migratory properties and apoptosis
resistance.3 The anti-apoptotic signals are at least partially
mediated by the epidermal growth factor receptor (EGFR)
pathway, which is transactivated by TGF-b through a
mechanism that involves upregulation of the EGFR ligands
and activation of themetalloprotease TACE/ADAM17 respon-
sible for their shedding.4,5
Many efforts have been done in the recent years for a better
understanding of spatial requirements on TGF-b signaling,
including endocytic TGF-b receptors trafficking. Strong pieces
of evidence support that TGF-b receptors can be located both
in clathrin-coated pits and caveolin/cholesterol-enriched lipid
rafts.6,7 A pioneer study from Di Guglielmo et al.8 proposed
that Smad2 phosphorylation would require clathrin-dependent
endocytosis, whereas TGF-b receptors internalization via
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caveolae/lipid rafts would inhibit its signaling. From then,
different studies have suggested that the endocytic pathways’
role on TGF-b signaling depend on the cell type and a general
rule about the role of endocytosis in TGF-b signaling is not well
understood yet.9 In hepatocytes, Smad activation is in a large
extent accomplished on the hepatocyte plasma membrane in
an AP-2 complex-dependent manner, being unnecessary the
formation of clathrin-coated pits.10 In contrast, the non-Smad/
AKT pathway activation requires caveolin-1 (Cav1)-depen-
dent endocytosis,10 which is required for counteracting
apoptosis.11
Cav1 is required for caveolae formation, which regulates
not only endocytosis, but also lipid metabolism and energy
homeostasis.12 The localization of membrane receptors in the
lipid raft pushed to investigate the role of Cav1 in regulating
signaling events. In the case of epidermal growth factor (EGF)
signaling, it was proposed that non-caveolae-coated pits are
involved in the compartmentalization and internalization of the
EGFR, although caveolin-rich domains may be required for
signaling.13 In this line of evidence, different studies revealed
an important role for Cav1 in EGFR-induced effects on cell
proliferation and migration.14,15
In this work, we have examined the role of Cav1 in the anti-
apoptotic signals induced by TGF-b in hepatocytes, postulat-
ing that it may be required for TGF-b-mediated regulation of
EGFR signaling. Using different experimental approaches
and an immortalized hepatocyte cell line derived fromCav1 /
mice, we demonstrate that transactivation of the EGFR
pathway by TGF-b is impaired in Cav1 / hepatocytes.
However, Cav1 is not required for the cellular response to
EGFR ligands, but is necessary for TGF-b-mediated activa-
tion of the metalloprotease TACE/ADAM17, which is respon-
sible for shedding of EGFR ligands and requires an intact lipid
raft domain to be activated by TGF-b.
Results
Cav1 deficiency alters the balance between the pro- and
anti-apoptotic signals induced by TGF-b in hepatocytes.
In order to analyze the specific relevance of Cav1 in the
response to TGF-b, we have used an immortalized neonatal
hepatocyte cell line obtained from 3-day old Cav1 /
animals16 (see Materials and Methods section and
Supplementary Figure 1a). Cav1 / hepatocytes showed
an increased sensitivity to TGF-b in terms of cell death,
exhibiting a significant higher percentage of non-viable cells
when compared with Cav1þ /þ cells after 72 h of treatment
(Figures 1a–c). Activation of caspase-3, as a hallmark of
apoptosis, showed similar dynamics, being increased in
Cav1-deficient hepatocytes when compared with control
cells and remained high after 72 h of TGF-b treatment
(Figure 1d). Since TGF-b-induced apoptosis in hepatocytes
requires reactive oxygen species (ROS) production mediated
by a NADPH oxidase system (NOX4),17 we next analyzed
intracellular ROS content. Results indicated that the increase
in intracellular ROS content was a transient process in
Cav1þ /þ hepatocytes showing a maximum increase after
6-h treatment, decreasing at later times up to levels even
lower than those found in the untreated cells. However, in
knockout cells (Cav1 / ), increase in ROS levels were
constantly high through all the time (Figure 1e). All these
results indicate that apoptotic features induced by TGF-b in
immortalized neonatal hepatocytes are increased in the
absence of Cav1 expression. In fetal and neonatal hepato-
cytes, TGF-b simultaneously induces both pro- and
anti-apoptotic signals, whose final balance determines the
cell fate.2,4 Anti-apoptotic signals include the phospho-
inositol-3-kinase (PI-3K)/AKT pathway, MAPK/ERKs and
NFk-B pathways. Thus, we next examined whether the
increased apoptosis observed in Cav1-deficient hepatocytes
is caused by impairment in activation of survival signals,
triggered by TGF-b. Western blot analysis showed a
significant inhibition of AKT activation and decreased
phosphorylation of MAP kinases ERK1/2 in TGF-b-treated
Cav1 / cells (Figures 2a and b). In addition, TGF-b-
induced activation of pro-survival NFk-B signaling was also
attenuated in Cav1 / cells, which showed lower transloca-
tion of cytosolic p65 to the nucleus after treatment with the
cytokine (Figures 2c and d). Therefore, in the absence of
Cav1, the imbalance between pro- and anti-apoptotic
regulatory signals finally pushes cells to die.
Cav1 deficiency prevents transactivation of the EGFR
pathway by TGF-b in hepatocytes. TGF-b-induced
survival signals in hepatocytes and liver tumor cells require
transactivation of the EGFR pathway.4,18 We hypothesized
that EGFR transactivation by TGF-b could be perturbed in
the absence of Cav1. In Cav1þ /þ cells, TGF-b induced
phosphorylation of EGFR, examined both by western blot
(Figure 3a) and immunocytochemistry (Figure 3b). Inhibition
of the EGFR catalytic activity by the tyrphostin AG1478
showed that EGFR-mediated signaling is necessary to
rescue Cav1þ /þ hepatocytes from the expected TGF-b-
induced apoptotic fate (Supplementary Figure 2). However,
Cav1 / cells did not show EGFR phosphorylation in
response to TGF-b (Figures 3a and b), and treatment with
AG1478 did not alter cell viability (Supplementary Figure 2).
Lack of response was not due to differences in EGFR
expression, which was similar in Cav1þ /þ and Cav / cells
(Supplementary Figures 1b and c).
To exclude that the absence of EGFR transactivation by
TGF-b could be due to a defect acquired during development
of the Cav1 knockout mice and not to the mere absence of
Cav1, we reconstituted the expression of Cav1 in Cav1 /
cells. Ectopic expression of Cav1 in the immortalized Cav1 /
cell line led to a recovery of the wild-type phenotype, with a
decreased sensitivity in terms of cell death (Figure 4a) and
lower activation of caspase-3 (Figure 4b). It is important to
point out that the control cell line (þ IRES-GFP, a control
plasmid expressing only GFP) behaved as the parental cell
line. Then, activation of AKT and ERK1/2 were examined,
evidencing a recovery of AKT phosphorylation and an increase
in ERK1/2 phosphorylation in TGF-b-treated Cav1 / when
expression of Cav1 was restored (Figure 4c). Interestingly,
restitution of Cav1 rescued the transactivation of EGFR by
TGF-b in Cav1 / hepatocytes (Figure 4d). In order to
confirm the results observed in Cav1 / hepatocytes, we
knocked down Cav1 in Cav1þ /þ hepatocytes using a specific
siRNA approach. Downregulation of Cav1 was efficient using
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two siRNAs (Supplementary Figure 3) and the EGFR
phosphorylation after stimulation with TGF-b was severely
reduced in Cav1-silenced Cav1þ /þ cells (Supplementary
Figure 3). Therefore, we conclude that Cav1 is determinant for
the capacity of TGF-b to transactivate the EGFR pathway in
hepatocytes.
As we observed that the EGFR transactivation was
impaired in Cav1 / hepatocytes, a possibility was that
Cav1 is required for cell responses to extracellular EGFR
ligands. Although we realized that the use of heparin-binding
EGF-like growth factor (HB-EGF), as a positive control of
EGFR phophorylation, did not show differences between
Cav1þ /þ and Cav1 / cells (Figure 3), to fully assess this
result, we examined the response to other EGFR ligands such
as EGF or transforming growth factor-alpha (TGF-a). Cav1
deficiency did not prevent the response to any of them in
terms of receptor phosphorylation or activation of downstream
signals (Figures 5a and b). Furthermore, Cav1 deficiency did
not perturb either other cellular responses to EGF receptor
ligands, such as cell proliferation (Figure 5c), despite
Cav1 / cells showed higher proliferative ratio in response
to FBS, as we had previously described.16
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Figure 1 Cav1-deficient hepatocytes are more sensitive to TGF-b in terms of apoptosis. Cav1þ /þ and Cav1 / hepatocytes were treated with TGF-b (2 ng/ml) for
different times, after previous FBS starvation (16 h). (a) Cell viability was measured using trypan blue staining, expressed as percentage of viable and non-viable cells (N¼ 3).
(b) Cell viability was analyzed by internalization of propidium iodide (PI), expressed as percentage of PI-positive cells (N¼ 3). (c) Representative PI-staining images taken at
72 h of treatment. (d) Caspase-3 activity, expressed as arbitrary units per hour and per microgram of protein (N¼ 3). (e) Intracellular ROS production expressed as relative
percentage versus untreated cells (N¼ 3). Results expressed as mean±S.E.M. Statistical comparison using Student’s t-test to compare control versus 72-h TGF-b treatment
in each cell line (b) or two-way ANOVA with Bonferroni post hoc test to compare Cav1þ /þ and Cav1 / hepatocytes (a, b, d and e): *Po0.05; **Po0.01, ***Po0.001
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Cav1 deficiency impairs TGF-b-mediated TACE/ADAM17
activity. Hepatocytes express different EGFR ligands, such
as HB-EGF, TGF-a or Amphiregulin (Supplementary
Figure 4). In order to know whether Cav1 may influence
the expression of these ligands, we analyzed their transcript
levels by real-time PCR. Results indicated that Cav1 /
cells do not show decreased expression of EGFR ligands.
Even in the case of TGF-a, the levels were higher
(Supplementary Figure 4). Indeed, we focused on the
shedding of these EGFR ligands, which is required for
the binding to the EGFR and activation of this pathway.
We previously described that short-term activation of the
metalloprotease TACE/ADAM17 by TGF-b is required for
activation of the EGFR and pro-survival signals in hepato-
cytes.4 Taking this into consideration, here we wondered
whether this pathway could be impaired in Cav1 /
hepatocytes. Analysis of TACE/ADAM17 enzymatic activity
using a fluorimetric method demonstrated that Cav1þ /þ , but
not Cav1 / , hepatocytes responded to TGF-b increasing
its activity (Figure 6a). Afterward, we studied whether this
increase had functional consequences such as a decrease
in the shedding of EGFR ligands into the cell media in
TGF-b-treated Cav1 / cells. To this aim, we collected
conditioned media from FBS-starved Cav1þ /þ and
Cav1 / hepatocytes, either untreated or treated with
TGF-b to analyze their capacity to phosphorylate the EGFR
in control Cav1þ /þ cells. Conditioned media from Cav1þ /þ
cells treated with TGF-b induced the phosphorylation of the
EGFR, in contrast to conditioned media from TGF-b-treated
Cav1 / cells (Figure 6b). Long-term treatment of Cav1þ /þ
hepatocytes with TGF-b increased TACE/ADAM17 mRNA
levels (Figure 6c), which was dependent on the EGFR
pathway, since knockdown of EGFR levels with a specific
siRNA attenuated this response (Supplementary Figure 5).
Upregulation of TACE by TGF-b was not observed in
Cav1 / hepatocytes (Figure 6c). Interestingly, Cav1
restitution in Cav1 / hepatocytes led to a full recovery of
TACE/ADAM17 activation after TGF-b treatment (Figure 6d),
which reinforced and confirmed the importance of Cav1 in
TACE/ADAM17 activity regulation.
TACE/ADAM17 in lipid rafts is necessary for its
TGF-b-mediated activation. In search for a mechanism
that explains how Cav1 may regulate TACE/ADAM17, we
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postulated colocalization of both proteins in lipid rafts of
hepatocytes, as recently reported for vascular smooth
muscle cells and endothelial cells.19,20 Using a sucrose
gradient technique to obtain detergent-resistant membranes
(DRMs) fractions, we observed that a pool of TACE/ADAM17
is localized in DRMs (identified by the presence of ganglio-
side GM1) in Cav1þ /þ hepatocytes (Figure 7a). This was not
the case in Cav1 / cells, where the amount of TACE/
ADAM17 in DRMs is highly reduced (Figure 7a). This result
demonstrates that Cav1 is necessary for TACE/ADAM17
localization in lipid rafts in hepatocytes. We also evaluated
whether Cav1-dependent DRMs localization of TACE is
regulated by TGF-b, particularly in stages when the
metalloprotease is more active. We obtained DRMs from
cells treated with TGF-b and observed an increase of TACE
in DRMs in Cav1þ /þ hepatocytes, but not in Cav1 / cells
(Figure 7a). Finally, as we found that TACE/ADAM17
localization in lipid rafts was increased after TGF-b
treatment, we examined the effect of lipid raft disruption by
cholesterol removal with methyl-b-cyclodextrin (MbC). MbC
dramatically decreased TGF-b-induced TACE/ADAM17 acti-
vation in Cav1þ /þ hepatocytes (Figure 7b), an effect that
was reversed by treatment of cells with extracellular
cholesterol (Supplementary Figure 6a). Furthermore, other
milder cholesterol-binding agents, such as filipin III or
nystatin, also inhibited TACE/ADAM17 activation by
TGF-b (Supplementary Figure 6b). We conclude that Cav1
is required for TACE/ADAM17 activation upon localization to
lipid rafts.
Discussion
The basic elements of the TGF-b pathwaywere detailed at the
end of the last century. However, how the intracellular
trafficking affects the TGF-b signal traveling from the cell
membrane to the nucleus, how posttranslational regulation of
receptors and Smads regulates signaling and/or how the
context determines the cellular response to TGF-b are open
questions yet.7,21–23 In hepatocytes, TGF-b induces both pro-
and anti-apoptotic signals, the latter mediated by the EGFR
pathway, which is transactivated by TGF-b through a
mechanism that involves upregulation of the EGFR ligands
and activation of themetalloprotease TACE/ADAM17 respon-
sible for their shedding.4,5 Cav1, the major component of
caveolae, had been also suggested to be necessary for
TGF-b induction of anti-apoptotic signaling in hepatocytes,
although the specific molecular mechanism is not well
understood yet.10,11 In this work, we demonstrate that in
immortalized neonatal mice hepatocytes, Cav1 is required for
TGF-b-mediated transactivation of the EGFR that initiates
intracellular signal cascades, such as MAPKs/ERKs and
PI-3K/AKT pathways, which directly prevent TGF-b-induced
upregulation of the NADPH oxidase NOX4, which is required
for its pro-apoptotic response.5 Indeed, failure in transactiva-
tion of the EGFR pathway increases ROS production and cell
death.17 The molecular mechanism requires the participation
of the TACE/ADAM17, a metalloprotease responsible for the
shedding of the EGFR ligands.24 Our results indicate that
Cav1 determines TACE/ADAM17 localization in lipid rafts in
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hepatocytes, which in turn is necessary for the TGF-b
transactivation of the EGFR. Different lines of evidence
support our conclusions: (1) in immortalized Cav1 /
hepatocytes, transactivation of the EGFR pathway by TGF-
b is reduced, which correlates with the lack of activation of
TACE/ADAM17; (2) the restitution of Cav1 in Cav1 /
hepatocytes recapitulates wild-type phenotype features both
in terms of EGFR transactivation and TACE/ADAM17 activa-
tion; (3) TACE/ADAM17 localizes to DRMs; (4) the
localization of TACE/ADAM17 in DRMs increases in response
to TGF-b only in the presence of Cav1. TGF-b-dependent
ERK1/2 and AKT phosphorylation was decreased in
Cav1 / cells, although extracellular EGFR ligand-depen-
dent ERKs and AKT phosphorylation was even increased in
Cav1 / cells. Furthermore, basal expression of EGFR
ligands is not lower in Cav1 / cells. This corroborates and
strengthens our conclusion that it is the TACE/ADAM17-
dependent EGFR ligand shedding what is highly sensitive to
Cav1 expression.
In support of the hypothesis that Cav1 is required for
TACE/ADAM17 activation, it was suggested that its activity
could be regulated by cholesterol in the plasma membrane.25
Our results after treatment with cholesterol scavengers (MbC,
filipin III or nystatin), confirm this hypothesis and therefore are
demonstrative that the integrity of lipid rafts is indeed
necessary for TACE/ADAM17 activity. However, lipid
raft-independent functions for TACE/ADAM17 have been
also proposed.26 The requirement of cholesterol-rich domains
for TACE/ADAM17 function could be cell type dependent
and/or it could depend on the protein substrate.
Another important indirect conclusion of our study is that
Cav1 is not required for the mitogenic response of hepato-
cytes to EGFR ligands such as EGF, TGF-a or HB-EGF.
Pioneer studies in the nineties suggested that a cross talk
between the EGFR and caveolins could govern EGFR
signals. Activation of the EGFR was localized in non-caveolar
membrane domains.27 However, EGFRs are initially concen-
trated in caveolae and rapidly move out of this membrane
domain in response to EGFR ligands.28 Caveolin was
proposed to be an inhibitor of the kinase domain of the EGFR,
thus impairing its signaling.29 Caveolae do not appear to be
involved in the endocytosis of EGF, which is mostly clathrin
dependent,30 although recent works suggest that it could be
also internalized by other pathways.31 Sustained evidence
suggests that EGF stimulates the caveolae/raft-dependent
endocytic pathway, which has been proposed to have relevant
consequences on other cellular signals.14,32 In human tumor
cells, EGFR-mediated caveolae-dependent endocytosis
disrupts cell–cell adhesion and causes EMT due to E-cad-
herin endocytosis33 and regulates integrin-mediated cell
behavior through internalization and segregation into different
intracellular compartments of integrins.34 The results
presented in this study suggest that cell responses to EGFR
ligands in terms of receptor phosphorylation, cell proliferation
and survival are Cav1 independent in hepatocytes. However,
further work is required for a detailed analysis of the role of
Cav1 on other cell responses related to the pro-tumorigenic
effects of the EGFR pathway and that will require the use of
liver tumor cells in the study.
Although the role of Cav1 in cancer is controversial, its
status has been proposed to be one of the causative factors
for the invasion and poor prognosis of liver tumors, in
particular hepatocellular carcinoma (HCC).35,36 Overexpres-
sion of Cav1 is observed along HCC progression and could
contribute to promote tumor growth and metastatic potential,
through increase in tumor cell motility and invasiveness.36
Interestingly, well differentiated cell lines exhibit low and
TGF-b-inducible Cav1 protein levels, whereas poorly
differentiated and highly invasive HCC cell lines show high
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comparison using two-way ANOVA with Bonferroni post hoc test as shown in the
figure: *Po0.05; **Po0.01
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Cav1 expression.37 Poorly differentiated HCC cells show
autocrine production of TGF-b, which is responsible for its
migratory and invasive capacity.38 The results presented in
this manuscript suggest that high expression of Cav1 in liver
tumor cells would switch the response to TGF-b from a
suppressor to a tumorigenic factor. Indeed, Cav1/lipid rafts
are required for the activation of TACE/ADAM17 by TGF-b,
which in turn activates the EGFR, whose signal transduction
pathways compensate its anti-mitogenic and pro-apoptotic
signals, allowing cells to respond to its pro-tumorigenic
effects.4,18,39 We previously reported that TACE/ADAM17
activation is a requirement for TGF-b-induced transactivation
of the EGFR in hepatocytes. Although TGF-b induces TGF-a
and HB-EGF in adult rat hepatocytes, they show a poor
response to this cytokine in terms of EGFR transactivation
because expression of TACE/ADAM17 is very low in these
cells and the shedding/activation of the EGFR ligands is
prevented. In contrast, liver tumor cells express high levels of
TACE/ADAM17 and show higher capacity to transactivate the
EGFR pathway in response to TGF-b.40 Due to this differential
response, TGF-b is a suppressor factor for adult quiescent
hepatocytes, but not for hepatoma cells, where it plays a dual
role, both suppressing and promoting carcinogenesis.
Importantly, inhibition of TACE/ADAM17 in fetal hepatocytes
or in hepatoma cells switch the TGF-b function toward
apoptosis and growth suppression.4,40 As TACE/ADAM17 is
also required for TGF-b-induced growth/survival signals in
breast cancer41,42 or gastric cancer43 cells, as well as for
promotion of motility and invasiveness by TGF-b in glioma
cells,44 the mechanism described in this work could have
transcendence in the pro-tumorigenic effects that TGF-b
exerts in many other tumors.
Materials and Methods
Reagents and antibodies. Human recombinant TGF-b1 and AG1478 were
from Calbiochem (La Jolla, CA, USA). EGF was kindly gifted by Serono Lab
(Madrid, Spain). Human recombinant HB-EGF, human recombinant TGF-a, MbC,
filipin III from Streptomyces filipinensis, nystatin and water-soluble cholesterol
were from Sigma-Aldrich (St. Louis, MO, USA). The antibodies used were: mouse
anti-b-actin (clone AC-15) from Sigma-Aldrich, rabbit anti-phospho-Akt (Ser473)
(D9E) XP, rabbit anti-Akt, rabbit anti-phospho-EGFR (Tyr1068) (D7A5) XP, rabbit
anti-EGFR, rabbit anti-phospho-p44/42 MAPK (Thr202/Tyr204), rabbit anti-p44/42
MAPK were from Cell Signaling Technology (Beverly, MA, USA), mouse anti-
Caveolin-1 from BD Biosciences (Franklin Lakes, NJ, USA), rabbit anti-Ki67 from
AbCam (Cambridge, UK), rabbit anti-TACE/ADAM17 (807-823) from Calbiochem,
rabbit anti-NFkB p65, rabbit anti-TbRI (H-100, used in immunocytochemistry),
rabbit anti-TbRI (R-20, used in western blot) and rabbit anti-TbRII (C-16) from
Santa Cruz Biotechnologies (Dallas, TX, USA). Secondary antibodies: Alexa Fluor
488-conjugated anti-rabbit and anti-mouse from Molecular Probes (Eugene, OR,
USA) and ECL Mouse IgG, and Rabbit IgG, HRP-Linked antibodies from GE
Healthcare (Buckinghamshire, UK). GM1 was detected with horseradish
peroxidase-tagged cholera toxin B subunit from Sigma (St. Louis, MO, USA).
Cell culture conditions. Immortalized neonatal hepatocytes from wild type
(Cav1þ /þ ) and caveolin-1 knockout (Cav1 / ) mice were kindly provided by
Paloma Martı´n-Sanz (IIBM Alberto Sols, Madrid, Spain). Isolation and
immortalization of neonatal hepatocytes from Cav1þ /þ and Cav1 / mice
has been previously described.16,45,46 In order to validate our experimental model,
we confirmed that Cav1 knockout cell line does not express Cav1 (Supplementary
Figures 1a and d). We also tested that both cell lines showed no differences in the
expression of the TGF-b receptors type 1 and 2 (Supplementary Figures 1b–d).
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Figure 7 TACE/ADAM17 localization in lipid rafts is necessary for its TGF-b-mediated activation. Cav1þ /þ and Cav1 / cell lines were treated with TGF-b (2 ng/ml) at
different times after previous FBS starvation (16 h). (a) Western blot of subcellular fractions from Cav1þ /þ and Cav1 / cells obtained using a sucrose gradient, ganglioside
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ADAM17 activity expressed as percentage of activity/untreated control (N¼ 3). Cells were treated with MbC 30 min before TGF-b treatment in order to disrupt lipid rafts by
removing cholesterol from membranes. Results expressed as mean±S.E.M. Statistical comparison using two-way ANOVA with Bonferroni post hoc test: *Po0.05;
**Po0.01; ***Po0.001
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Reconstitution of Cav1 / cell line (Cav1 / þ IRES-GFP and Cav1 /
þCav1) was kindly performed in Miguel A. del Pozo Lab (CNIC, Madrid, Spain)
as previously described.47 For cell culture, cells were grown in DMEM from Lonza
(Basel, Switzerland), supplemented with 10% fetal bovine serum (FBS), penicillin
(120mg/ml), streptomycin (100mg/ml) and amfoterycin B (2.5mg/ml) and
maintained in a humidified atmosphere of 37 1C, 5% CO2. For experiments, cells
at 60% confluence were serum-starved for 16 h and treated with different factors:
TGF-b1 (2 ng/ml), EGF (20 ng/ml), HB-EGF (20 ng/ml) and TGF-a (20 ng/ml).
When indicated, the following products were added 30 min before the other factors
(TGF-b1 or HB-EGF) and maintained along the experiment: AG1478 (20 mM),
MbC (2.5mM), filipin III (0.5mM) and nystatin (25 mM). For reversion of the MbC
effect by treatment of cells with extracellular cholesterol (1 mM), this lipid was
added after 30-min treatment with MbC, waiting for an additional 1 h before adding
TGF-b1, and maintained along the experiment.
Analysis of cell viability. Cell viability was analyzed using both trypan blue
and propidium iodide (PI). For trypan blue dye cells were trypsinized collecting the
media. After 5-min centrifugation at 1200 r.p.m., cells were resuspended in 50 ml
PBSþ 1 : 10 v/v trypan blue. Viable and non-viable (blue dyed) cells were counted
in a Neubauer chamber, counting eight squares for condition, with duplicates.
Results are expressed as percentage of viable and non-viable cells. For PI
staining, 1mg/ml (final concentration) PI from Sigma-Aldrich was added to each
well (from a 12-well multiwell plate). Afterward, PI-positive cells were counted in a
phase contrast microscope Olympus IX70 (Tokyo, Japan). Results were
expressed as percentage of PI-positive cells.
Measurement of intracellular redox state. The oxidation-sensitive
fluorescent probe 20,70-dichlorodihydrofluorescein diacetate (H2DCFDA; from
Invitrogen, Carlsbad, CA, USA) was used to analyze the total intracellular content
of ROS as previously described.39 Fluorescence was measured in a Microplate
Fluorescence Reader Fluostar Optima (BMG LABTECH, Ortenberg, Germany)
and expressed as percentage of control after correction with protein content.
Analysis of caspase-3 activity. Fluorimetric analysis of caspase-3 activity
was determined as described previously,4 using the Caspase-3 fluorogenic
substrate Ac-DEVD-AMC from BD Pharmingen (Franklin Lakes, NJ, USA), with
20mg of protein extract. Protein concentration of cell lysates was determined using
Bradford Reagent from Sigma-Aldrich. A unit of caspase-3 activity is the amount of
active enzyme necessary to produce an increase in 1 fluorescence unit and results
are presented as units of caspase-3 activity/h/mg protein.
Western blot analysis. Total protein extracts and western blot procedure
were carried out as previously described.5,39 Primary antibodies were used at
1 : 1000, except b-actin (1 : 5000), secondary antibodies were used at 1 : 5000.
Protein concentration was measured with BCA Protein Assay kit (Pierce,
Rockford, USA). Densitometric analysis of protein bands intensity was performed
using ImageJ software (Public domain, NIH, Bethesda, MD, USA).
Dot blot analysis. A 2-ml drop of protein extract is applied onto nitrocellulose
membrane and let to dry during 6–8 h. The following procedure is the same as for
western blot analysis.
Immunocytochemistry studies. Fluorescence microscopy studies were
performed as described previously.40 Cells were fixed with 4% paraformaldehyde
in PBS for 20 min at RT for NFkB-p65 and Ki67 stainings and with methanol for
2 min at  20 1C for phospho-EGFR, TbRI, TbRII and caveolin-1 stainings.
Coverslips were then incubated with primary antibody diluted in 1% BSA for 2 h at
RT for NFkB-p65 and Ki67 or overnight at 4 1C for all other antibodies (dilutions:
NFkB-p65 1 : 50; Ki67 1 : 100; p-EGFR 1 : 200; TbRI 1 : 200, TbRII 1 : 200 and
caveolin-1 1 : 200). After several washes with PBS, the samples were incubated
with Alexa Fluor 488-conjugated anti-rabbit or anti-mouse for 1 h at RT (1 : 200).
After washing with PBS, nuclear DNA was stained with DAPI (Sigma-Aldrich) and
samples were mounted in MOWIOL 4-88 reagent (Calbiochem). Cells were
visualized in a Nikon-80I microscope (Tokyo, Japan) with the appropriate filters,
except in the Supplementary Figure 1, where an Olympus BX-60 microscope
(Tokyo, Japan) and a Leica TCS-NT confocal microscope (Wetzlar, Germany)
were used (as specified in its figure legend). Representative images were taken
and edited in Adobe Photoshop software.
TACE/ADAM17 activity measurement. Fluorimetric measurement of
TACE/ADAM17 activity was determined as described previously,4 using
10mM TACE Substrate IV from Calbiochem, with 10 mg of protein extract.
Fluorescence was measured in a Microplate Fluorescence Reader Fluostar
Optima every 5 min during 1 h at 37 1C (excitation: 320 nm; emission: 420 nm).
Protein concentration of cell lysates was determined using Bradford reagent from
Sigma-Aldrich. Results were expressed as percentage of activity compared with
the untreated control (100%).
Analysis of gene expression. RNeasy Mini Kit (Qiagen, Valencia, CA,
USA) was used for total RNA isolation. Reverse transcription (RT) was carried out
using the High Capacity Reverse Transcriptase kit (Applied Biosystems, Foster
City, CA, USA), with 500 ng of total RNA from each sample for complementary
DNA synthesis.
For real-time quantitative PCR, expression levels were determined in duplicate in
an ABIPrism7700 System, using the Sybr Green PCR Master Mix (Applied
Biosystems) or in a LightCycler 480 System, using LightCycler 480 SYBR Green I
Master Mix (Roche, Basel, Switzerland). Reactions were performed with the
following mouse-specific primers:
TACE/
ADAM17
50-GGGTTTTGCGACATGAATGG-30 forward
50-GAAAACCAGAACAGACCCAAC-30 reverse
EGFR 50-CTCCATGCTTTCGAGAACCTAG-30 forward
50-ATGATCACATCCCCATCACTG-30 reverse
TbRI 50-CCAAACCACAGAGTAGGCAC-30 forward
50-ACCAATAGAACAGCGTCGAG-30 reverse
TbRII 50-GGAGAAGTGAAGGATTACGAGC-30 forward
50-CACACGATCTGGATGCCC-30 reverse
HB-EGF 50-CCCCTATACACATATGACCACAC-30 forward
50-CAACTTCACTTTCTCTTCACTTTCC-30 reverse
TGF-a 50-CTGGGTATCCTGTTAGCTGTG-30 forward
50-GTACTGAGTGTGGGAATCTGG-30 reverse
AREG 50-AGATACATCGAGAACCTGGAGG-30 forward
50-AGAGACAAAGATAGTGACAGCTAC-30 reverse
L32 50-ACAATGTCAAGGAGCTGGAG-30 forward
50-TTGGGATTGGTGACTCTGATG-30 reverse
18S 50-CGAGACTCTGGCATGCTAA-30 forward
50-CGCCACTTGTCCCTCTAAG-30 reverse
Knockdown assays. For transient siRNA transfection, cells were transfected
at 50% confluence using TransIT-siQuest (Mirus, Madison, WI, USA) at 1 : 300
dilution in complete medium, according to the manufacturer’s recommendation,
with a final siRNA concentration of 50 nM during 8 h. Oligos were obtained from
Sigma-Genosys (Suffolk, UK). The oligo sequences were as follows:
Unsilencing 50-GUAAGACACGACUUA UCGC-30
Cav1(1) 50-ACGUAGACUCCGAGGGACA-30
Cav1(2) 50-GCAAAUACGUAGACUCCGA-30
EGFR 50-GCGAUAAGUCGUGUCUUAC-30
The unsilencing siRNA used was selected from previous works.39
Preparation of detergent-resistant membrane (DRM) fractions.
DRM fractions were purified as described in Navarro-Lerida et al.48 Two confluent
p100 plates were scraped from each cell line and resuspended in 335ml (final
volume) MES-buffered saline (MBS: 25 mM MES, pH 6.5, 0.15 M NaCl, 1 mM
PMSF plus 1% Triton X-100) at 4 1C. Cells were homogenized by a minimum of 10
strokes through a syringe (0.5 16 mm) on ice. The homogenate was brought up
to 670ml by adding 335ml 80% sucrose in MBS, and placed at the bottom of a
Beckman TLS-55 2.2 ml Ultraclear tube (Beckman Coulter, Brea, CA, USA). The
discontinuous sucrose gradient (40–30–5%) was formed by sequentially loading
670ml 30% sucrose and 670ml 5% sucrose in MBS. Separation was performed by
centrifuging at 50 000 r.p.m. for 3 h in a TLS-55 rotor (Beckman Coulter) at 4 1C
(using an Optima MAX-TL ultracentrifuge, Beckman Coulter). A light, scattered
band confined to the 5–30% sucrose interface was observed that contained most
caveolin-1 protein and excluded most other proteins. Six 335-ml fractions were
collected, starting from the bottom of the tube. An equal volume of cold acetone
was added to each fraction and the proteins precipitated overnight at 4 1C. Protein
pellets were collected by centrifugation at 13 000 r.p.m. and air-dried for 2 h to
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eliminate acetone traces. The protein precipitates were then analyzed by SDS-
PAGE and western blot, or dot blot in the case of GM1.
Statistics. All data represents at least three experiments and are expressed as
the mean±S.E.M. Differences between groups were compared using Student’s
t-test (when comparing two groups), one-way ANOVA with Tukey’s
multiple comparison test (when comparing more than two groups and considering
one independent variable) or two-way ANOVA with Bonferroni post hoc test
(when comparing differences between groups considering two independent
variables). All statistical tests were conducted using GraphPad Prism (La Jolla,
CA, USA). Differences were considered statistically significant at *Po0.05,
**Po0.01 and ***Po0.001.
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